DALLAS, March 3,
2022 /PRNewswire/ -- Lantern Pharma (NASDAQ:
LTRN), a clinical stage biopharmaceutical company using its
proprietary RADR® artificial intelligence ("A.I.")
platform to transform the cost, pace, and timeline of oncology drug
discovery and development, announced today that it will host a
conference call on Thursday, March 10th,
2022 at 4:30 p.m. Eastern Time
/ 1:30 p.m. Pacific Time.
Management intends to discuss the financial and operating
results for the fourth quarter and fiscal year ended December 31, 2021 and provide guidance on
upcoming milestones. The call will be led by Panna Sharma, President and Chief Executive
Officer of Lantern Pharma. He will be joined on the call by other
members of the management team.
To register for the live webinar, please sign up here:
https://zoom.us/webinar/register/6316442460324/WN_IpjiP_QpT5ClHzrW1U7GwA
A replay of the webinar will be available on the investor
relations section of the Company's website:
ir.lanternpharma.com.
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage oncology-focused
biopharmaceutical company leveraging its proprietary
RADR® A.I. platform and machine learning to
discover biomarker signatures that identify patients most likely to
respond to its pipeline of genomically-targeted therapeutics.
Lantern is currently developing four drug candidates and an ADC
program across eight disclosed tumor targets, including two phase 2
programs. By targeting drugs to patients whose genomic profile
identifies them as having the highest probability of benefiting
from the drug, Lantern's approach represents the potential to
deliver best-in-class outcomes. More information is available at:
www.lanternpharma.com and Twitter @lanternpharma.
Lantern Pharma Investor Relations Contact:
Nicole Leber
IR@lanternpharma.com
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our
RADR® platform in identifying drug candidates and
patient populations that are likely to respond to a drug candidate;
our strategic plans to advance the development of our drug
candidates and antibody drug conjugate (ADC) development program;
estimates regarding the development timing for our drug candidates
and ADC development program; our research and development efforts
of our internal drug discovery programs and the utilization of our
RADR® platform to streamline the drug development
process; our intention to leverage artificial intelligence, machine
learning and genomic data to streamline and transform the pace,
risk and cost of oncology drug discovery and development and to
identify patient populations that would likely respond to a drug
candidate; estimates regarding potential markets and potential
market sizes; sales estimates for our drug candidates and our plans
to discover and develop drug candidates and to maximize their
commercial potential by advancing such drug candidates ourselves or
in collaboration with others. Any statements that are not
statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "objective," "aim," "upcoming," "should," "will,"
"would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the
risk that our research and the research of our collaborators may not be successful, (iii)
the risk that none of our product candidates has received FDA
marketing approval, and we may not be able to successfully
initiate, conduct, or conclude clinical testing for or obtain
marketing approval for our product candidates, (iv) the risk that
no drug product based on our proprietary RADR®
A.I. platform has received FDA marketing approval or
otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and
Exchange Commission on March 10,
2021. You may access our Annual Report on Form 10-K for the
year ended December 31, 2020 under
the investor SEC filings tab of our website at
www.lanternpharma.com or on the SEC's website
at www.sec.gov. Given these risks and uncertainties, we can
give no assurances that our forward-looking statements will prove
to be accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-inc-to-report-fourth-quarter-and-full-year-2021-financial-results-on-march-10-2022-301494704.html
SOURCE Lantern Pharma